Medication Description: Isadrin (Isadrinum)
ISADRIN (Isadrinum). 1- (3, 4-dioxyphenyl) -2-isopropylaminoethanol hydrochloride, or N-isopropylnorradinerenaline hydrochloride.
Abroad is produced in the form of a hydrochloride optics , Neoepinephrine, Norisodrin, Novodrin, etc.
White crystalline powder. Easily soluble in water. Aqueous solutions have a slightly greenish tint.
Isopropylnoradrenaline (izadrin) was obtained in 1938 in the synthesis of adrenaline derivatives.
Chemically, isopropylnonradrenaline belongs to the catecholamine group and differs in structure from adrenaline in that the methyl radical in the amino group [NH-CH3] is replaced by isopropyl [NH-CH (CH3) 2].
In the pharmacological study of isopropylnorradrenaline, it was found that, while retaining some of the properties of adrenaline, it also differs in action from the latter. So, it contributes to the relaxation of the bronchi, but does not cause vasoconstriction and increase in peripheral blood pressure; at the same time, like adrenaline, it causes an increase and increase in heart rate.
In this regard, it was suggested that there are different types of adrenoreceptors in the body, with which adrenaline, isopropylnoradrenaline and similar compounds can interact. The final idea of the presence of two main groups of adrenoreceptors (a - and b -adrenoreceptors) was formulated in 1948 (Ahlquist). Subsequently, subgroups of these receptors were identified: a 1 - and a 2 -, b 1 - and b 2 -adrenoreceptors.
Isopropylnoradrenaline was recognized as the first representative of a new group of adrenergic substances - b-adrenergic, or b -adrenostimulants.
Following this, new b-adrenostimulators began to appear. A characteristic structural feature of these compounds is the presence of a side chain (alkylisopropyl, alkyl tert-butyl or other), bringing them closer to the structure of isopropylnoradrenaline.
The pharmacological and therapeutic effect of isopropylnorradrenaline (izadrin) is explained by its stimulating effect on b -adrenoreceptors.
The effect of izadrina extends simultaneously to b 1 - and b 2 -adrenoreceptors, therefore the effect on the bronchi, the cardiovascular system and other organs equipped with b-adrenoreceptors is not selective.
Currently, there are a number of new b-adrenostimulators that have a selective effect on b 1 - and b 2 -adrenoreceptors.
Due to the characteristic stimulating effect on b -adrenoreceptors, izadrin has a strong bronchodilator effect, causes an increase and increase in heart contractions, increases cardiac output.
However, it reduces the total peripheral vascular resistance (due to arterial vasoplegia), lowers blood pressure, reduces the filling of the ventricles of the heart. The drug increases the myocardial oxygen demand.